Lactose India FY26 Net Profit Rises 17% to ₹606.28 Lakh
Lactose (India) Limited reported a 17.4% increase in net profit to ₹606.28 lakh for FY26, driven by a 40.3% rise in revenue to ₹16,329.01 lakh. The company's Q4 net profit surged to ₹187.69 lakh, while its merger with Vitanosh Ingredients awaits regulatory approvals.
*this image is generated using AI for illustrative purposes only.
Lactose (India) Limited has announced its audited financial results for the fourth quarter and financial year ended March 31, 2026. The Board of Directors approved the results during a meeting held on May 20, 2026. Statutory auditors M/s. DMKH & Co. issued an audit report with an unmodified opinion on the financial results.
For the financial year ended March 31, 2026, the company reported a net profit of ₹606.28 lakh, an increase of 17.4% from ₹516.29 lakh in the previous year. Revenue from operations rose significantly by 40.3% to ₹16,329.01 lakh from ₹11,639.93 lakh in FY25. Total income for the year stood at ₹16,436.20 lakh.
Financial Performance for FY26
The company's profitability improved alongside revenue growth. Profit before tax for the year increased to ₹862.01 lakh from ₹691.78 lakh in the prior year. Basic earnings per share (EPS) for the year rose to ₹4.82 from ₹4.10 in the corresponding period last year.
The following table summarizes the key financial metrics for the year ended March 31, 2026, compared to the previous year:
| Particulars | Year Ended 31-Mar-26 (₹ in Lakhs) | Year Ended 31-Mar-25 (₹ in Lakhs) |
|---|---|---|
| Revenue from operations | 16,329.01 | 11,639.93 |
| Total Income | 16,436.20 | 11,785.32 |
| Total Expenses | 15,574.20 | 11,093.54 |
| Profit before tax | 862.01 | 691.78 |
| Net Profit | 606.28 | 516.29 |
| Basic EPS (₹) | 4.82 | 4.10 |
Quarterly Results and Segment Information
For the quarter ended March 31, 2026, the company reported a net profit of ₹187.69 lakh, compared to ₹64.22 lakh in the same quarter of the previous year. Revenue from operations for the quarter stood at ₹4,576.61 lakh. Lactose (India) Limited operates in a single reportable business segment, Pharmaceuticals.
Corporate Developments
The Board noted that shareholders approved the Scheme of Arrangement for the merger with Vitanosh Ingredients Private Limited at an Extraordinary General Meeting held on March 28, 2026. The scheme is pending final approvals from the Securities and Exchange Board of India and the National Company Law Tribunal. Consequently, no effect of the merger has been given in the financial results for the quarter ended March 31, 2026.
Additionally, the company issued and allotted 15,00,000 convertible share warrants in December 2024, receiving ₹652.50 lakh towards 25% of the subscription amount. The company also recognized an estimated incremental impact of ₹6.54 lakhs under employee costs due to the New Labour Codes notified by the Government of India.
Historical Stock Returns for Lactose
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.77% | -5.65% | +0.49% | -11.94% | +14.24% | +292.23% |
How will the merger with Vitanosh Ingredients Private Limited impact Lactose (India) Limited's revenue mix and profit margins once SEBI and NCLT approvals are obtained?
Given the 40.3% revenue growth in FY26, can Lactose (India) Limited sustain this trajectory, and what key pharmaceutical segments or geographies are likely to drive future expansion?
What will be the full financial impact of converting the 15,00,000 share warrants issued in December 2024, and how might the resulting equity dilution affect EPS going forward?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
